{
  "title": "Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC",
  "url": "https://www.jacc.org/doi/10.1016/j.jacadv.2025.102204",
  "summary": [
    {
      "type": "bullet",
      "text": "**KEY FINDING**: 3 FDA-approved ATTR-CM therapies now rely on PRO endpoints to demonstrate patient benefit."
    },
    {
      "type": "bullet",
      "text": "**TACTICAL WIN [ROADMAP]**: Integrate AI-driven analytics to predict patient adherence and optimize ePRO workflows."
    },
    {
      "type": "bullet",
      "text": "**MARKET SIGNAL [ðŸ”´ URGENT]**: New FDA guidance prioritizes PRO integration in cardiovascular trials by Q1 2025."
    },
    {
      "type": "bullet",
      "text": "**CONCERN**: Self-selection bias could inflate PRO improvements, requiring rigorous study design safeguards."
    }
  ],
  "model": "granite4:tiny-h"
}